Recurrent thoracic malignant tumors
Conditions
Interventions
Sponsors
Department of Radiation Oncology for Thoracic Tumor, Shanghai Proton and Heavy Ion Center
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Informed consent achieved; Have the ability to comply with the plan; Aged between 18 and 80 years; Cytological or histological diagnosed primary thoracic malignant tumors (non-small cell lung cancer, small cell lung cancer, sarcoma, and malignant thymoma); Received 1 cycle of standard conventional radiotherapy which terminated more than 6months before recurrence; Metastasis was excluded; Patients who can not tolerate or reject concurrent chemotherapy; The KPS score >=60, and the ECOG general status score is 0-1; The anticipated survival will be >= 12 months; Adequate organs' functions; The position of the lesions can meet the requirements of the design of the radiation field; Patients can hold their positions for more than 30 minutes as the treatment requires. The residual movement of normal tissue and tumor at the pathway of beam must be < = 5mm (breath control technique can be used).
Exclusion criteria
Exclusion criteria: Accompanied with other malignant tumors which were not well controlled; The adverse effects of previous treatment have not been recovered; The radiotherapy plan cannot meet the minimum dose coverage and dose volume limit requirements, or can not meet the dose limitation of the normal organs; Have history of thoracic radiation including hypofractionated radiotherapy, brachytherapy or 2 or more cycles of standard conventional radiotherapy before recurrence; Have cardiac pacemakers or other metal prostheses in the radiation area whose function could be affected by high-energy radiation; Doctors think that carbon ion radiotherapy will not benefit the patient; Have diseases that may affect the treatment of carbon ions; Accompanied with serious complications that may affect carbon ion therapy; Unable to understand the purpose of treatment or unwilling/unable to sign informed consent; No capacity for civil conduct or limited capacity for civil conduct. Other situations that physicians do not think it is appropriate to participate in this clinical research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dose Limited Toxicity;Local control; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival; | — |
Countries
China
Contacts
Public ContactMAO JING-FANG
Shanghai Proton and Heavy Ion Center
Outcome results
None listed